"Dexamethasone" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An anti-inflammatory 9-fluoro-glucocorticoid.
Descriptor ID |
D003907
|
MeSH Number(s) |
D04.210.500.745.432.769.344 D04.210.500.908.238
|
Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Dexamethasone".
Below are MeSH descriptors whose meaning is more specific than "Dexamethasone".
This graph shows the total number of publications written about "Dexamethasone" by people in this website by year, and whether "Dexamethasone" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1994 | 3 | 11 | 14 |
1995 | 7 | 4 | 11 |
1996 | 2 | 8 | 10 |
1997 | 1 | 2 | 3 |
1998 | 2 | 6 | 8 |
1999 | 4 | 10 | 14 |
2000 | 5 | 11 | 16 |
2001 | 3 | 4 | 7 |
2002 | 4 | 16 | 20 |
2003 | 5 | 20 | 25 |
2004 | 9 | 5 | 14 |
2005 | 4 | 13 | 17 |
2006 | 7 | 6 | 13 |
2007 | 5 | 16 | 21 |
2008 | 7 | 16 | 23 |
2009 | 5 | 11 | 16 |
2010 | 6 | 12 | 18 |
2011 | 6 | 15 | 21 |
2012 | 5 | 14 | 19 |
2013 | 6 | 15 | 21 |
2014 | 4 | 21 | 25 |
2015 | 8 | 20 | 28 |
2016 | 9 | 9 | 18 |
2017 | 7 | 16 | 23 |
2018 | 7 | 13 | 20 |
2019 | 4 | 15 | 19 |
2020 | 9 | 15 | 24 |
2021 | 4 | 15 | 19 |
2022 | 0 | 16 | 16 |
2023 | 2 | 12 | 14 |
2024 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Dexamethasone" by people in Profiles.
-
Daratumumab for patients with myeloma with early or late relapse after initial therapy: subgroup analysis of CASTOR and POLLUX. Blood Adv. 2024 01 23; 8(2):388-398.
-
More intensive therapy as more effective treatment for frail patients with multiple myeloma [corrected]. Blood Adv. 2023 10 24; 7(20):6275-6284.
-
The role of corticosteroids in the palliation of dyspnea in cancer patients: an evidence-based review. Curr Opin Support Palliat Care. 2023 12 01; 17(4):270-276.
-
Impact of Dosing and Duration of Dexamethasone on Serious Corticosteroid-Related Adverse Events. J Pain Symptom Manage. 2024 Jan; 67(1):59-68.
-
Addition of daratumumab to lenalidomide, bortezomib, and dexamethasone for transplantation-eligible patients with newly diagnosed multiple myeloma (GRIFFIN): final analysis of an open-label, randomised, phase 2 trial. Lancet Haematol. 2023 Oct; 10(10):e825-e837.
-
Outcomes of Autologous Stem Cell Transplantation in Patients with Ultra-High-Risk Multiple Myeloma. Transplant Cell Ther. 2023 Dec; 29(12):757-762.
-
Mezigdomide plus Dexamethasone in Relapsed and Refractory Multiple Myeloma. N Engl J Med. 2023 Sep 14; 389(11):1009-1022.
-
Single-agent lenalidomide maintenance after upfront autologous stem cell transplant for newly diagnosed multiple myeloma: The MD Anderson experience. Am J Hematol. 2023 10; 98(10):1571-1578.
-
Does Bortezomib-Dexamethasone-Rituximab-Cyclophosphamide Play a Role in the Treatment of Waldenstr?m's Macroglobulinemia? J Clin Oncol. 2023 08 20; 41(24):4059-4060.
-
Plain language summary of the MAIA study of daratumumab plus lenalidomide and dexamethasone for the treatment of people with newly diagnosed multiple myeloma. Future Oncol. 2023 Apr; 19(13):887-895.